| 主权项 |
1. A method comprising:
a. obtaining a composition for parenteral or enteral administration comprising a galacto-rhamnogalacturonate in a pharmaceutical acceptable carrier, and b. administering to a subject in need thereof an effective dose of the composition that results in at least one of the following: at least 5% reduction of lung edema, at least 5% reduction of lung pathology severity scores associated with lung fibrosis, at least 5% reduction of lung tissue hydroxyproline accumulation, at least 5% reduction of expression of pro-inflammatory proteins, at least 5% reduction of expression of fibrogenic proteins,
wherein the subject in need thereof has at least one of the following: a primary or secondary lung fibrotic disease. |
